Findings from Scientific Researchers: Ortho Evra Leads to Pulmonary Embolism. Lawsuits currently being filed against drugmaker Johnson & Johnson

Weitz & Luxenberg is no longer accepting ReNu with MoistureLoc cases.

On January 18, 2008, the Food and Drug Administration was forced to update the warnings section of physician labeling for Johnson & Johnson’s (J&J) birth control patch Ortho Evra. They now include scientific data from a new research study that found the patch increases the risk of a dangerous medical condition, venous thromboembolism (VTE), when compared with traditional birth control pills. VTE can lead to pulmonary embolism.

The agency originally updated the Ortho Evra (ethinyl estradiol/norelgestromin) label with information from two epidemiology studies, one of which found that use of the transdermal patch doubled a patient’s risk of VTE when compared with birth control pills.

Ellen Relkin, an attorney with the Weitz & Luxenberg P.C. Drugs and Medical Devices Litigation unit, has been at the forefront of Ortho Evra litigation, having been appointed in July 2006 as the State Court Liaison in the Ortho Evra Multi-District Litigation (MDL) by the Honorable David Katz of the United States District Court for the Northern District of Ohio.

Previous to that she was appointed to the Executive Committee of the Steering Committee of the Ortho Evra Multi-District Litigation in May 2006. She is also lead counsel in the New Jersey Ortho Evra litigation.

Our firm has won numerous cases involving dangerous pharmaceuticals, including Vioxx, achieving a $13.5 million verdict against Merck & Co. The firm’s other active pharmaceutical litigations include actions against the manufacturers of Bextra, ReNu, Celebrex, Ortho Evra, Gadolinium dye and Medtronic's Sprint Fidelis Leads.

If you have been harmed by Ortho Evra, we may be able to help. Please complete the form below for a free lawsuit evaluation of your potential case. We will be in touch shortly.

Weitz & Luxenberg is no longer accepting ReNu with MoistureLoc cases.

see also:

FDA Warning, 1.18.08 FDA: Ortho Evra Users at Higher Risk for VTE and Pulmonary Embolism
FDA Changes Ortho Evra label after second study cites pulmonary risk

Firm's Press Release Weitz & Luxenberg Lawyer Echoes Concern Over New Warning on Ortho Evra
Additional study cites serious blood clot risk: Ortho Evra Lawyer

Updated FDA Warnings FDA Continues to Update Warnings to Label of Ortho Evra--attorney info
Read on for information regarding Updated FDA Warnings to Ortho Evra